how does glutathione s-transferase cause drug resistance in cancer cells

how does glutathione s-transferase cause drug resistance in cancer cells Unveiling the Role of Protein Breast Resistance: Insights into the Signaling Pathways and Therapeutic Implications Glutathione transferases: substrates, inihibitors and

Name: how does glutathione s-transferase cause drug resistance in cancer cells Unveiling the Role of Protein Breast Resistance: Insights into the Signaling Pathways and Therapeutic Implications Glutathione transferases: substrates, inihibitors and
Brand: southroadsurgery.com.au
SKU: 82365844102
Price: 27.14 USD
Availability: InStock
Rating: 4.704700000000001 (24 reviews)

Glutathione transferases: substrates, inihibitors and pro drugs in cancer and neurodegenerative diseases Oncogenesis Overexpression of Glutathione S Transferases in Human Diseases: Drug Targets and Therapeutic Implications Cancer drug resistance: an evolving paradigm Nature Reviews Cancer Glutathione S transferase : a potential role in antitumor therapy DDDT Dove Medical Press The Different Mechanisms of Cancer Drug Resistance: A Brief Review PMC Glutathione S transferase Theta 2 causes drug resistance by inhibiting arsenic trioxide induced ferroptosis in pancreatic ductal adenocarcinoma ScienceDirect

SKU: 82365844102 · From southroadsurgery.com.au

4.7

USD27.14 USD48.14

Pay in 4 interest-free payments of $6.79 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

Can it be purchased in bulk

While distinct from glutathione, these pathways work together

A study found the safety and effectiveness of adding EGCG to GA in patients with relapsingremitting MS

This collaboration led to the development of SHIRATAMA BOOSTER, a dietary supplement that simplifies the intake of glutathione

We recently discovered that many human plasma proteins are also specifically converted into chaperone-like holdases by N-chlorination and as such, gain the ability to protect other proteins from HOCl-induced aggregation [37]

demonstrated in patients with advanced colorectal cancer treated by either anti-EGFR inhibition or without, the expression of autophagy proteins Beclin-1 and LC3 were not only associated with advanced colorectal cancer, but those with higher expression of these proteins experienced worse objective response rates, and shorter progression free survival